Su Bing-Nan, Shen Ren-Juan, Liu Zhuo-Lin, Li Yang, Jin Zi-Bing
School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
Beijing Tongren Eye Center, Beijing Tongren Hospital, Beijing Institute of Ophthalmology, Capital Medical University, Beijing, China.
Front Aging Neurosci. 2022 Aug 10;14:948279. doi: 10.3389/fnagi.2022.948279. eCollection 2022.
Mutation in the gene is the most common cause of inherited retinal dystrophy (IRD), including non-syndromic retinitis pigmentosa (RP) and Usher syndrome II (USH2). Gene editing and therapy targeting , especially the hotspot region, would benefit a large proportion of IRD patients. In this study, we comprehensively analyzed the genetic spectrum of the gene, aiming to identify global hot spot mutations in -related IRDs and differences in hot spot regions across continents.
A retrospective -related IRD study was conducted, including our IRD cohort, and reported studies worldwide.
A total of 3,972 mutated alleles of approximately 1,935 patients were collected from 33 cohort studies worldwide, containing 102 alleles of 51 patients in our IRD cohort. Mutations in exon 13 were the most common, reaching 18.4% globally and a higher frequency of 22% in America, 19.2% in Europe, and a lower 12% in East Asia. Pathogenic mutations that affected 10 of the 72 exons of , exon 2, exon 13, exon 41-43, exon 50, exon 54, exon 57, exon 61, and exon 63 in total were responsible for half of global mutant alleles. With base editors including adenine base editor (ABE), cytidine base editor (CBE), and glycosylase base editor (GBE), 76.3% of single nucleotide variations (SNVs) and 58% of all mutations in are correctable. Meantime, four novel pathogenic mutations were revealed in our IRD cohort, p. (Val1130Cysfs72), p. (Ala2139fs14), p. (Gly4139Arg), and p. (Val4166Cysfs*7).
In this study, we revealed four novel mutations, expanding the spectrum of mutations, and importantly presented global hotspot exons and mutations of as well as the proportion of SNVs that can be restored by different base editors, providing a perspective for exploring high-efficiency and broader-reaching gene editing and gene therapies.
该基因的突变是遗传性视网膜营养不良(IRD)最常见的病因,包括非综合征性视网膜色素变性(RP)和II型Usher综合征(USH2)。针对该基因,特别是热点区域进行基因编辑和治疗,将使很大一部分IRD患者受益。在本研究中,我们全面分析了该基因的遗传谱,旨在确定与该基因相关的IRD中的全球热点突变以及各大洲热点区域的差异。
开展了一项与该基因相关的IRD回顾性研究,包括我们的IRD队列以及全球已报道的研究。
从全球33个队列研究中收集了约1935例患者的总共3972个该基因突变等位基因,其中我们的IRD队列中有51例患者的102个等位基因。第13外显子的突变最为常见,在全球达到18.4%,在美国频率更高,为22%,在欧洲为19.2%,在东亚较低,为12%。影响该基因72个外显子中的10个的致病突变,即第2外显子、第13外显子、第41 - 43外显子、第50外显子、第54外显子、第57外显子、第61外显子和第63外显子,总共占全球该基因突变等位基因的一半。使用包括腺嘌呤碱基编辑器(ABE)、胞嘧啶碱基编辑器(CBE)和糖基化酶碱基编辑器(GBE)在内的碱基编辑器,该基因中76.3%的单核苷酸变异(SNV)和58%的所有突变是可校正的。同时,在我们的IRD队列中发现了四个新的致病突变,即p.(Val1130Cysfs72)、p.(Ala2139fs14)、p.(Gly4139Arg)和p.(Val4166Cysfs*7)。
在本研究中,我们发现了四个新突变,扩展了该基因突变谱,重要的是展示了该基因的全球热点外显子和突变以及不同碱基编辑器可修复的SNV比例,为探索高效且更具广泛适用性的基因编辑和基因治疗提供了一个视角。